Form 4: Director Andy Pasternak Acquires Stock Options

Director Andy Pasternak of Context Therapeutics Inc. acquired 45,000 stock options with an exercise price of $0.576, vesting on June 24, 2027.

Summary

• Director Andy Pasternak acquired 45,000 stock options in Context Therapeutics Inc.
• The exercise price for these options is $0.576 per share.
• The options are set to vest and become exercisable on June 24, 2027, or at the Issuer's 2027 annual meeting of stockholders, provided continued service.
• This transaction was reported on June 26, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard stock option grant to a director, which is a common incentive mechanism rather than a direct indicator of immediate company performance or strategic shifts.

Positives

• Director's acquisition of stock options indicates a potential belief in the company's future value.
• The option grant provides a long-term incentive for the director to remain with the company.

Risks

• The vesting of options is contingent on continued service, meaning the director could leave before the options become exercisable.
• The value of the options is subject to the future stock price performance of Context Therapeutics Inc.

Future Outlook

The stock options granted to Director Andy Pasternak have a vesting date of June 24, 2027, and an expiration date of June 23, 2036, indicating a long-term incentive tied to continued service and company performance.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology and pharmaceutical sectors, often used to align executive interests with shareholder value over the long term.

Stakeholder Impact

• Shareholders: The grant of options to a director aligns their interests with shareholders, potentially encouraging actions that benefit the company's stock price.
• Employees: This type of grant is standard and does not directly impact other employees unless they are also recipients of similar equity compensation.
• Management: Reinforces the long-term commitment of the director to the company.

Next Steps

• Director Andy Pasternak is expected to continue service with Context Therapeutics Inc. for the options to vest.
• The company's stock performance will determine the ultimate value of the acquired options.

Key Dates

Keywords

Form 4, SEC Filing, Stock Options, Insider Trading, Context Therapeutics Inc., CNTX, Director, Beneficial Ownership, Securities Exchange Act